Predict your next investment

Cure Genetics company logo
HEALTHCARE | Biotechnology
curegenetics.com

See what CB Insights has to offer

Founded Year

2016

Stage

Unattributed | Alive

Total Raised

$28.66M

About Cure Genetics

Suzhou Cure Genetics Biotechnology, dba Cure Genetics, is a transformational biotechnology company focused on CRISPR gene-editing technology for cell therapy drug applications.

Cure Genetics Headquarter Location

Room 510, Building A4, Shengwu Nami Park Suzhou Industry Park No.218

Suzhou, Jiangsu,

China

Latest Cure Genetics News

Cure Genetics, Boehringer to develop AAV vectors for gene therapy

Jan 19, 2021

X Chinese biotechnology firm Cure Genetics has partnered with Boehringer Ingelheim for the development of novel Adeno-Associated Virus (AAV) vectors to be used in gene therapies. Cure Genetics partners with German company Boehringer to develop AAV vectors for gene therapy. Subscribe to our email newsletter The companies will leverage Cure Genetics’ VELP platform to develop the vectors. Under the partnership, Boehringer’s experience in disease biology and gene therapy development will be combined with Cure Genetics’ AAV expertise in library construction and in vivo AAV screening, with an aim to develop new AAV serotypes for patients. Clinical applications of existing AAV serotypes are limited by low transduction efficiency, low tissue specificity and immunogenicity. Hence, finding new serotypes is critical for the majority, if not all, AAV-based gene therapies. Cure Genetics claims that its VELP platform incorporates key methodical innovations including a comprehensive strategy of engineering a plasmid library with high complexity and an effective ratio. Its AAV production protocol also provides high genome-capsid correspondence and physiologically relevant models for vector selection and validation. The company further noted that the protocol enables shorter process to find the ‘right’ AAV vectors with all possible effects covered. Cure Genetics Chief Operating Officer Qiushi Li said: “This is the very first time that a global pharmaceutical group is collaborating with a Chinese biotech in the cutting-edge field of AAV vector engineering. We appreciate the recognition of Boehringer Ingelheim’s recognition of our VELP platform. “Novel AAV vectors enlarging the therapeutic window is key to unfolding the potential of gene therapy, which is also Cure Genetics’ innovative focus. We believe, together with visionary partners like Boehringer Ingelheim, the quality of life for more patients in need can be improved by next-generation gene therapy.” Boehringer Ingelheim aims to develop next generation medical breakthrough, and gene therapy is one of the focused areas which its team of Research Beyond Borders is exploring. The company further said that it can leverage Cure Genetics’ VELP technology platform not only to increase the efficiency of the novel AAV screening, but also to further expand its efforts in the area of gene therapy development. Boehringer Ingelheim China External Innovation Hub had initiated the collaboration with Cure Genetics. Last December Boehringer agreed to acquire NBE-Therapeutics , a clinical-stage Swiss biotechnology company for €1.18bn to enhance its cancer pipeline portfolio. Do you have interesting content to share with us? Enter your email address so we can get in touch.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cure Genetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cure Genetics is included in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,726 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,708 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

S

Synthetic Biology

235 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

Cure Genetics Patents

Cure Genetics has filed 2 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Clusters of differentiation
  • Genetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/30/2018

Molecular biology, Transplantation medicine, Genetics, Biotechnology, Ribonucleases

Application

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/30/2018

00/00/0000

Grant Date

00/00/0000

Title

Subscribe to see more

Related Topics

Molecular biology, Transplantation medicine, Genetics, Biotechnology, Ribonucleases

Subscribe to see more

Status

Application

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.